TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06375928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic biliary drainage
Description: Decompression of the bile duct by endoscopic aproach.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-expandable metallic stent (SEMS)
Description: Self-expandable metallic stent (SEMS) deployment:~* Covering: Uncovered or Partially Covered. Non covered if gallbladder is present.~* Size: 10x40mm or 10x60mm or 10x80mm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumen-apposing metal stent (LAMS) and double-pigtail plastic stent (DPPS)
Description: Lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPPS) deployment:~* LAMS size: 6x8mm or 8x8mm. Consider 10x10mm if bile duct \> 18mm.~* DPPS size: 7Fr x 3-7cm.
Study: NCT04792255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid artery stenting with standard contrast media protocol
Description: Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the standard contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting with reduced contrast media protocol
Description: Radial, brachial or femoral arterial access is gained by using the Seldinger technique. The common carotid artery (CCA) is catheterized. Selective angiography is performed from the anteroposterior and lateral view without magnification. Initial angiograms are performed with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the common carotid artery. The carotid arterial lesion is crossed and an embolic protection device is deployed in the internal carotid artery. Carotid artery stenting is performed in a standard fashion. Post-stenting angiographies are obtained with the reduced contrast media protocol in anteroposterior and lateral views without magnification with the sheath placed in the CCA. Pre- and post-stenting angiographies are performed with the same sheath position. DSA and DVA images will be calculated on a commercially available image processing workstation and the Kinepict Medical Imaging Tool.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Carotid Duplex Ultrasound
Description: Pre- and postinterventional assessment of the treated internal carotid artery.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Carotid Duplex Ultrasound
Description: Pre- and postinterventional assessment of the treated internal carotid artery.
Study: NCT06331533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: Intradermal botulinum toxin A was applied to the treatment side

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl was injected into the placebo side
Study: NCT04892459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Ad5 vectored vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant SARS-CoV-2 Ad5 vectored vaccine
Description: This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactive SARS-CoV-2 vaccine (Vero cell)
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactive SARS-CoV-2 vaccine (Vero cell)
Description: This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.
Study: NCT05780151

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methodological intervention
Description: All three arms will receive the same clinical intervention but will differ in their level of decentralisation, the methodological intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methodological intervention
Description: All three arms will receive the same clinical intervention but will differ in their level of decentralisation, the methodological intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Methodological intervention
Description: All three arms will receive the same clinical intervention but will differ in their level of decentralisation, the methodological intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toujeo
Description: All participants in the study will receive Toujeo® (insulin glargine 300 U/mL). During the treatment period, Toujeo® injection will be administered once daily at the same time as the participant's previous basal insulin was injected, for participant previously treated with once daily injection. In case of previous insulin treatment administered twice a day, the time of injection of Toujeo® will have to be agreed between the physician and the participant before first administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toujeo
Description: All participants in the study will receive Toujeo® (insulin glargine 300 U/mL). During the treatment period, Toujeo® injection will be administered once daily at the same time as the participant's previous basal insulin was injected, for participant previously treated with once daily injection. In case of previous insulin treatment administered twice a day, the time of injection of Toujeo® will have to be agreed between the physician and the participant before first administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toujeo
Description: All participants in the study will receive Toujeo® (insulin glargine 300 U/mL). During the treatment period, Toujeo® injection will be administered once daily at the same time as the participant's previous basal insulin was injected, for participant previously treated with once daily injection. In case of previous insulin treatment administered twice a day, the time of injection of Toujeo® will have to be agreed between the physician and the participant before first administration.
Study: NCT05670795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Follicle Stimulating Hormone
Description: clinical pregnancy rates

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Follicle Stimulating Hormone and Clomiphene Citrate
Description: clinical pregnancy rates
Study: NCT06170658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lenses
Description: Daily disposable, silicone hydrogel investigational lenses for one week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Lenses
Description: Daily disposable, silicone hydrogel investigational lenses for one week
Study: NCT06510725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mutitarget tDCS
Description: Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to DLPFC and M1 alternately for ten consecutive weekdays, with each target stimulated for 5 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-target tDCS
Description: Subjects will receive 20 minutes of active transcranial direct current stimulation at 2mA applied to M1 for ten consecutive weekdays.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Subjects will receive 20 minutes of sham transcranial direct current stimulation. Ramps up and down will be applied for 15 seconds each at the beginning and end of the session. The current will be 0 mA during the interval between the initial and final ramps. Subjects will undergo stimulation once a day for ten consecutive weekdays.
Study: NCT06170658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lenses
Description: Daily disposable, hydrogel commercially available lenses for one week

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Lenses
Description: Daily disposable, hydrogel commercially available lenses for one week
Study: NCT06271707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Description: an ultrasound guided left stellate ganglion block with 5 mL of 0.5% bupivacaine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: an ultrasound guided left stellate ganglion block with 5 mL of saline
Study: NCT04155619

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No change in meal timing
Description: Participants will eat within an ≥11-hour daily period (no change in meal timing habits).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No change in meal timing
Description: Participants will eat within an ≥11-hour daily period (no change in meal timing habits).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No change in light exposure
Description: Participants will not change their light exposure habits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No change in light exposure
Description: Participants will not change their light exposure habits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Feeding
Description: Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Feeding
Description: Participants will eat within an 8-hour daily period early in the day, starting within 2 hours of waking up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed Light Therapy
Description: Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Timed Light Therapy
Description: Participants will use bright light therapy for 60 minutes between 6 am - 3 pm, blue light-blocking glasses for one hour before bedtime, and blackout curtains at night.
Study: NCT06089837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC5026 oral tablet
Description: 2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days.~Oral doses of EC5026 tested in each cohort:~4 mg loading dose on Day 1 / 2 mg Maintenance dose on Days 2-7 (Cohort 1) 8 mg loading dose on Day 1 / 4 mg Maintenance dose on Days 2-7 (Cohort 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: 2 sequential cohorts of 8 subjects randomly assigned to receive multiple ascending oral doses of EC5026 (n=6 per cohort) or matching placebo (n=2 per cohort) for 7 consecutive days. Subject assigned to the Placebo Arm will receive 7 days of matching placebo oral tablets in each Cohort.
Study: NCT06422689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol and budesonide inhalation aerosol
Description: Participants will receive a fixed-dose combination of albuterol (90mcg) and budesonide (80mcg) administered as 2 inhalations (180mcg/160mcg) via pressurized metered dose inhaler (pMDI) as needed for asthma symptoms, for up to 12 inhalations (6 doses) in a 24-hour period.
Study: NCT05316584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote monitoring
Description: See prior description of the intervention.
Study: NCT06575686

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Given PO
Study: NCT06651281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tulisokibart
Description: Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to tulisokibart
Description: Placebo matching SC tulisokibart
Study: NCT06497218

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blinklab diagnostic device
Description: Blinklab is a non-invasive diagnostic device for Autism Spectrum Disorder
Study: NCT04484025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ebselen
Description: Glutathione peroxidase mimetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ebselen
Description: Glutathione peroxidase mimetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo containing excipients
Study: NCT06436742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-119
Description: Intravenous infusion of ARGX-119

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo
Study: NCT04665648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: 6 mg nicorandil iv. just before coronary intervention, 6mg/h ivgtt. up to 48h after coronary intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo iv. just before coronary intervention, ivgtt. up to 48h after coronary intervention
Study: NCT06414395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex (Dexmedetomidine) 200 MCG in 2 ML Injection
Description: The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex (Dexmedetomidine) 200 MCG in 2 ML Injection
Description: The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex (Dexmedetomidine) 200 MCG in 2 ML Injection
Description: The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: C group: Patients received saline infusion over 10 minutes
Description: the group will receive normal saline infusion over 10 minutes.
Study: NCT05821634

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized intervention condition: Cognitive behavioral therapy skills
Description: An 11-session cognitive behavioral therapy (CBT) skills based intervention will be delivered to participants randomized to the personalized intervention. Influential constructs will be identified using the person specific digital phenotyping model, targeted using CBT skills, and tracked across sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic control condition: Cognitive behavioral therapy skills
Description: Participants randomized to this condition will receive an 11-session CBT skills based treatment targeting a non-personalized construct selected from the person-specific digital phenotyping model.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tracking control condition: Supportive counseling
Description: Participants randomized to this condition will receive 11 supportive counseling sessions that are non-directive in nature (providing support and validation for non-acute weekly stressors). Participants will continue digital phenotyping, controlling for the effect of counseling and digital phenotyping.
Study: NCT05383365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital Myofascial Release(MFR) with sham Deep Neck Flexor(DNF)exercise
Description: The treatment includes Suboccipital MFR in the supine position.The therapist places the supinated forearm on the bed and positions the tips of the middle three fingers inferior to the occiput bone and the head is supported by the thenar eminences.The therapist will develop a line of tension through the suboccipital tissues by supinating the forearms and pulling apart two hands from each other;Then, for the second level in the first position of hands,pressure is applied to the anterior and superior direction.The pressure is held and increased until the therapist feels the decrease of muscle tone.These techniques last 10 minutes.~Another intervention in this group is the sham DNF exercise with a Pressure Biofeedback Unit(PBU).Considering that minimum detective change with PBU is 15 mmHg; After placing the airbag of PBU under the occiput bone in the supine position and inflating it to a base pressure of 11 mmHg,the participant will increase the pressure to 12 mmHg by nodding action.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Neck Flexor(DNF)exercise with sham Suboccipital Myofascial Release(MFR)
Description: The treatments include the DNF exercise with a PBU. The treatment is performed in the supine position and the airbag is placed under the occiput bone and is inflated to a base pressure of 20 mmHg. The participant will increase and hold the pressure to a special point by nodding action. The exercise is repeated for 3 sets, in each set 2 mm Hg is added to the pressure. The pressure will be increased from 22 to 32 mm Hg during 4-week of treatment, and each goal is held for 10 seconds and repeated 10 times. There will be 5 sec of rest between each repetition and 2 min of rest between each set.~Another intervention in this group is sham MFR. The therapist's hands will be placed only inferior to the occipital bone and a superficial touch is applied without any upward or lateral pressure. sham treatment in this group, like the opposite group, lasts 10 minutes.
Study: NCT06061003

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Anatomical Education with Fractured Bone Models
Description: Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. In the practical session, anatomical structures, their relationships, and arrangements will be demonstrated to the practice group using a model of a fractured wrist.

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Anatomical Education with Standard Bone Models
Description: Participants will undergo a 2-hour training session, consisting of 60 minutes of theory and 60 minutes of practice. The theoretical lesson, supported by 2D images illustrating wrist anatomy, types of fractures, and rehabilitation based on fracture type, will be simultaneously delivered to both groups. Following this, the practical group will receive a 60-minute hands-on session using 3D-printed digital models of radius and ulna fractures. These training sessions will be scheduled in the morning hours, on a day when students have no other classes between 9 am and 12 pm, to minimize mental fatigue and exhaustion. The control group will receive the same practical session using a standard anatomical model.